Global Alzheimer’s Platform Foundation (GAP) has introduced a new mobile health site to lower barriers to the participation of underrepresented communities in Alzheimer’s clinical trials.
Around 1% of the African Americans and Hispanics with Alzheimer’s take part in trials where therapies may be available for them.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This mobile research site is intended to address this disparity and from 19 July, the mobile site will make stops in the Orlando, Florida metropolitan area, US.
GAP president John Dwyer, Jr said: “Increasing diversity in Alzheimer’s clinical trials is the first best step we can take towards advancing the drug development pipeline to better treat — or eventually cure — this terrible disease.
“By bringing clinical trials to people in their communities, we can help reduce the barriers that may inhibit people from participating in Alzheimer’s research studies.”
These problems could comprise transportation expenses and language barriers, among others.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIndividuals who are usually at risk of developing Alzheimer’s can take part in pre-screening visits at every GAP mobile site stop, which requires only 15 to 20 minutes compared to standard ones needing several hours.
The screenings will aid in determining if an individual can take part in an Alzheimer’s prevention study, which is the first GAP-facilitated fully supported prevention trial.
Free memory screenings, brain health education and information from other regional partners on community resources are the other resources provided by the mobile site at each stop.
GAP Recruitment and Strategic Initiatives associate director Tamiko Magee-Rodgers said: “Helping connect traditionally underrepresented people with educational resources, as well as building trust in communities where Alzheimer’s is so prevalent, is something that we’re excited to do.”
A patient-centric non-profit organisation, GAP focuses on expediting the delivery of new treatments for neurological disorders by lowering trial cost and duration.
Currently, over 100 research centres across the globe are part of its network.
